Regranion, LLC is a clinical-stage pharmaceutical company delivering breakthrough solutions for autoimmune skin diseases by targeting a conserved pathway that contributes to hyperinflammation...
RGRN-305, our lead product, is an orally delivered potent small molecule inhibitor of heat shock protein 90 (HSP90) that has demonstrated activity as a broad-spectrum anti-inflammatory molecule and clinical safety and efficacy in patients with autoimmune skin disease.